JP2022507514A - Erkインヒビター及びその使用 - Google Patents

Erkインヒビター及びその使用 Download PDF

Info

Publication number
JP2022507514A
JP2022507514A JP2021526509A JP2021526509A JP2022507514A JP 2022507514 A JP2022507514 A JP 2022507514A JP 2021526509 A JP2021526509 A JP 2021526509A JP 2021526509 A JP2021526509 A JP 2021526509A JP 2022507514 A JP2022507514 A JP 2022507514A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
independently
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507514A5 (cg-RX-API-DMAC7.html
Inventor
リーブス,コリー,エム.
オーボイル,ブレンダン,エム.
ヒルフ,ジャスティン,エー.
コンクリン,ディラン
マクダーモット,マルティナ,エス.
オーブライアン,ニール,エー.
パラッツォロ,マイケル,ジェイ.
スレイモン,デニス
ウィッテンバーガー,スティーブン,ジェイ.
ローソン,オリバー,シー.
バートバーガー,マイケル,ディー.
ストルツ,ブライアン,エム.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2022507514A publication Critical patent/JP2022507514A/ja
Publication of JP2022507514A5 publication Critical patent/JP2022507514A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021526509A 2018-11-16 2019-11-15 Erkインヒビター及びその使用 Pending JP2022507514A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862768565P 2018-11-16 2018-11-16
US62/768,565 2018-11-16
US201962908965P 2019-10-01 2019-10-01
US62/908,965 2019-10-01
PCT/US2019/061750 WO2020102686A1 (en) 2018-11-16 2019-11-15 Erk inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2022507514A true JP2022507514A (ja) 2022-01-18
JP2022507514A5 JP2022507514A5 (cg-RX-API-DMAC7.html) 2022-12-09

Family

ID=70730924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526509A Pending JP2022507514A (ja) 2018-11-16 2019-11-15 Erkインヒビター及びその使用

Country Status (12)

Country Link
US (1) US12428416B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880677A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022507514A (cg-RX-API-DMAC7.html)
KR (1) KR20210130701A (cg-RX-API-DMAC7.html)
CN (1) CN113423707A (cg-RX-API-DMAC7.html)
AU (1) AU2019381808A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009430A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119988A1 (cg-RX-API-DMAC7.html)
IL (1) IL283106A (cg-RX-API-DMAC7.html)
MX (1) MX2021005171A (cg-RX-API-DMAC7.html)
SG (1) SG11202104404XA (cg-RX-API-DMAC7.html)
WO (1) WO2020102686A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531740A (ja) * 2004-04-02 2007-11-08 バーテックス ファーマシューティカルズ インコーポレイテッド Rockの阻害剤として有用なアザインドールおよび他のプロテインキナーゼ
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
WO2017085230A1 (en) * 2015-11-18 2017-05-26 Agv Discovery Azaindole derivatives and their use as erk kinase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200700751B (en) 2004-06-30 2008-08-27 Vertex Pharma Azalndoles useful as inhibitors of protein kinases
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
NZ590784A (en) * 2008-07-23 2012-12-21 Vertex Pharma Pyrazolopyridine kinase inhibitors
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
DE102009060174A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
US8697697B2 (en) 2011-01-04 2014-04-15 Kinentia Biosciences Llc Pyrazole derivatives as ERK inhibitors
US9096598B2 (en) 2011-10-03 2015-08-04 Merck Sharp & Dohme Corp. Azaindoles as Janus kinase inhibitors
EP2909206A1 (en) * 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
BR112015016580A2 (pt) 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
SI3052096T1 (en) * 2013-10-03 2018-04-30 Kura Oncology, Inc. EAQ inhibitors and application procedures
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CN107973783B (zh) * 2016-10-21 2024-09-06 正大天晴药业集团股份有限公司 作为erk抑制剂的苯胺嘧啶衍生物
CN108948002A (zh) 2017-05-19 2018-12-07 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531740A (ja) * 2004-04-02 2007-11-08 バーテックス ファーマシューティカルズ インコーポレイテッド Rockの阻害剤として有用なアザインドールおよび他のプロテインキナーゼ
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
WO2017085230A1 (en) * 2015-11-18 2017-05-26 Agv Discovery Azaindole derivatives and their use as erk kinase inhibitors

Also Published As

Publication number Publication date
MX2021005171A (es) 2021-10-01
BR112021009430A2 (pt) 2021-08-17
KR20210130701A (ko) 2021-11-01
US12428416B2 (en) 2025-09-30
AU2019381808A1 (en) 2021-05-27
IL283106A (en) 2021-06-30
WO2020102686A1 (en) 2020-05-22
CA3119988A1 (en) 2020-05-22
US20220002294A1 (en) 2022-01-06
EP3880677A4 (en) 2022-06-22
SG11202104404XA (en) 2021-05-28
CN113423707A (zh) 2021-09-21
EP3880677A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
US12428416B2 (en) ERK inhibitors and uses thereof
ES2974985T3 (es) Inhibidores de FGFR y métodos de uso de los mismos
JP6993985B2 (ja) イソキノリン-3イル-カルボキサミドならびにその調製および使用の方法
JP7023243B2 (ja) イソキノリン-3イル-カルボキサミドならびにその調製および使用の方法
JP5102839B2 (ja) 有糸分裂進行を阻害するための化合物
JP6342392B2 (ja) 置換型ピラゾロン化合物及び使用方法
CN114867735A (zh) Ras抑制剂
KR20240127909A (ko) Sos1 억제제로서의 아졸릴피리딘 피리다지논 아미드
TWI574962B (zh) 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途
JP2024516371A (ja) Egfr変異を有するがんを処置するためのアミノ置換ヘテロ環類
DK2947086T3 (en) UNKNOWN CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF
CN107922431A (zh) Hpk1抑制剂及其使用方法
TW202108572A (zh) Cdk抑制劑
CN107635986A (zh) 取代的喹喔啉衍生物
CN108430993A (zh) Tank-结合激酶抑制剂化合物
TW201444838A (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN114728934B (zh) 杂环衍生物、药物组合物和它们治疗或改善癌症的用途
CN115698004A (zh) 作为hpk1抑制剂的氮杂内酰胺化合物
JP2021531349A (ja) Cdkインヒビター及びその使用
HK40121832A (en) Oxazepine compounds comprising a 6-aza moiety and uses thereof
CN118459485A (zh) 用于治疗具有egfr突变的癌症的氨基取代杂环
HK40130280A (en) Azolylpyridine pyridazinone amide as sos1 inhibitor
HK40110722A (en) Cyclopentylpyrazole cdk2 inhibitors
HK40076319A (en) Ras inhibitors
HK40084694A (en) Azalactam compounds as hpk1 inhibitors

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240625